These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30355421)

  • 21. Bortezomib-induced pneumonitis during bortezomib retreatment in multiple myeloma.
    Yamaguchi T; Sasaki M; Itoh K
    Jpn J Clin Oncol; 2012 Jul; 42(7):637-9. PubMed ID: 22628610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pomalidomide-Induced Pulmonary Toxicity in Multiple Myeloma.
    Modi D; Mamdani H; Vettese T
    Am J Med Sci; 2015 Sep; 350(3):241-2. PubMed ID: 26200951
    [No Abstract]   [Full Text] [Related]  

  • 23. Impact of pomalidomide therapy in multiple myeloma: a recent survey.
    Kumar A; Porwal M; Verma A; Mishra AK
    J Chemother; 2014 Dec; 26(6):321-7. PubMed ID: 25004945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The efficacy and safety of pomalidomide in relapsed/refractory multiple myeloma in a "real-world" study: Polish Myeloma Group experience.
    Charlinski G; Grzasko N; Jurczyszyn A; Janczarski M; Szeremet A; Waszczuk-Gajda A; Bernatowicz P; Swiderska A; Guzicka-Kazimierczak R; Lech-Maranda E; Szczepaniak A; Wichary R; Dmoszynska A
    Eur J Haematol; 2018 Sep; 101(3):354-361. PubMed ID: 29882602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pomalidomide.
    Engelhardt M; Ajayi S; Reinhardt H; Müller SJ; Dold SM; Wäsch R
    Recent Results Cancer Res; 2018; 212():169-185. PubMed ID: 30069630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Case of thalidomide-induced interstitial pneumonia].
    Matsushima H; Oda T; Yamamoto M; Sato A; Hasejima N; Takezawa S
    Nihon Kokyuki Gakkai Zasshi; 2009 May; 47(5):438-42. PubMed ID: 19514509
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.
    Hanaizi Z; Flores B; Hemmings R; Camarero J; Sancho-Lopez A; Salmonson T; Gisselbrecht C; Laane E; Pignatti F
    Oncologist; 2015 Mar; 20(3):329-34. PubMed ID: 25673103
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pulmonary toxicity after long-term treatment with lenalidomide in two myeloma patients.
    Amraoui K; Belhadj K; Maître B; Jannière-Nartey C; Dupuis J
    Eur Respir Rev; 2013 Mar; 22(127):93-5. PubMed ID: 23457172
    [No Abstract]   [Full Text] [Related]  

  • 29. Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma.
    Mark TM; Coleman M; Niesvizky R
    Leuk Res; 2014 May; 38(5):517-24. PubMed ID: 24690110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pomalidomide for patients with multiple myeloma.
    Gras J
    Drugs Today (Barc); 2013 Sep; 49(9):555-62. PubMed ID: 24086951
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pomalidomide for multiple myeloma].
    Dougé A; Lemal R; Chaleteix C
    Bull Cancer; 2017 Sep; 104(9):707-713. PubMed ID: 28583668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Efficacy of pomalidomide in a multiple myeloma patient requiring hemodialysis].
    Kida M; Hirao M; Iizuka H; Hangaishi A; Usuki K
    Rinsho Ketsueki; 2016; 57(11):2339-2344. PubMed ID: 27941283
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a "real-world" study: the Royal Marsden Hospital experience.
    Sriskandarajah P; Pawlyn C; Mohammed K; Dearden CE; Davies FE; Morgan GJ; Boyd KD; Kaiser MF
    Leuk Lymphoma; 2017 Feb; 58(2):494-497. PubMed ID: 27439571
    [No Abstract]   [Full Text] [Related]  

  • 34. Hypersensitivity pneumonitis-like syndrome associated with the use of lenalidomide.
    Thornburg A; Abonour R; Smith P; Knox K; Twigg HL
    Chest; 2007 May; 131(5):1572-4. PubMed ID: 17494808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thalidomide induced nonspecific interstitial pneumonia in patient with relapsed multiple myeloma.
    Kang MH; Ju JH; Kim HG; Kang JH; Jeon KN; Kim HC; Lee GW
    Korean J Intern Med; 2010 Dec; 25(4):447-9. PubMed ID: 21179284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pomalidomide in the treatment of multiple myeloma - own experience and overview of literature].
    Adam Z; Pour L; Krejčí M; Vetešníková E; Sandecká V; Štork M; Čermáková Z; Pourová E; Ševčíková S; Král Z; Mayer J
    Vnitr Lek; 2016; 62(12):962-968. PubMed ID: 28139124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pomalidomide therapy for myeloma.
    Schey S; Ramasamy K
    Expert Opin Investig Drugs; 2011 May; 20(5):691-700. PubMed ID: 21413906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lenalidomide induced pneumonitis.
    Finch K; Sharma D; Wagner S
    J Oncol Pharm Pract; 2023 Jun; 29(4):971-974. PubMed ID: 36071644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Successful management of drug-induced skin rash in a relapsed multiple myeloma patient with pomalidomide desensitization].
    Hagihara M; Ide S; Ohara S; Uchida T; Inoue M; Hua J
    Rinsho Ketsueki; 2019; 60(2):137-139. PubMed ID: 30842382
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pomalidomide, dabrafenib mesylate, and trametinib dimethyl sulfoxide.
    Hussar DA; Kaminski JL
    J Am Pharm Assoc (2003); 2013; 53(5):550-8. PubMed ID: 24030134
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.